维普期刊资源整合服务平台（V6.5）

75篇 您的检索式：作者名="Gore SD"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Current therapy of myelodysplastic syndromes显示文摘	Zeidan AM Linhares Y Gore SD	2013	Blood Rev2013，27，5：	1
2	Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation显示文摘	Grigiths EA Gore SD Hooker C	2010	Leuk Lymphoma2010，51，9：	1
3	The clinical application of targeting cancer through histone acetylation and hypomethylation 显示文摘	Gilbert J Gore SD Herman JG	2004	Clin Cancer Res2004，10，14：	1
4	Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia显示文摘	Gore SD Gojo I Sekeres MA	2010	J Clin Oncol2010，28，6：	1
5	DNA methyltransferase and histone deaeetylase inhibitors in the treatment of myelodysplastie syndromes 显示文摘	Griffiths EA Gore SD	2008	Semin Hematol2008，45，1：	1
6	Combined methyitransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS,CMMoL and AML:clinical response,histone acetylation and DNA damage显示文摘	Gore SD Jiemjit A Silverman LB	2006	Blood2006，108，11：	1
7	Combined DNA methyhransferase and hislone deacetylase inhibition in the treatment of myeloid neoplasms显示文摘	Gore SD Baylin S Sugar E	2006	Cancer Res2006，66，：	1
8	Single cycle of arsenic trioxide based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia显示文摘	Gore SD Gojo l Sekeres MA	2010	J Clin Oncol2010，28，6：	1
9	Intravenous azacitidine for MDS显示文摘	Gore SD	2007	Clin Adv Hematol Oncol2007，5，：	1
10	Intravenous azaeitidine for MDS 显示文摘	Gore SD	2007	Clin Adv Hematol Oncol2007，5，：	1
11	Future directions in myelodysplastic-syndrome:newer agents and the role of combination approaches显示文摘	Gore SD Hermes-DeSantis ER		0，，：	1
12	Single cycle of arsenic ttrioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia 显示文摘	Gore SD Gojo I Sekeres MA	2010	J Clin Oncol2010，28，6：	1
13	Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia显示文摘	Gore SD Weng LJ Figg WD	2002	Clinical Cancer Research2002，8，4：	1
14	New ways to use DNA methyltransferase inhibi- tors for the treatment of myelodysplastic syndrome显示文摘	Gore SD	2011	He- matology Am Soc Hematol Educ Program2011，2011，：	1
15	Combined DNA methyllrans- ferase and histone deacetylase inhibition in the treatment of myeloid neoplasms 显示文摘	Gore SD Baylin S Sugar E	2006	Cancer Res2006，66，12：	1
16	Impact of the putative differentiationg agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia显示文摘	Gore SD Weng LJ Zhai S	2001	Clin Cancer Res2001，7，：	1
17	Arsenic trioxide-An old drug rediscovered 显示文摘	Emadi A Gore SD	2010	Blood Rev2010，24，：	1
18	Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia显示文摘	Gore SD Weng LJ Figg WD	2002	Clin Cancer Res2002，8，：	1
19	Single cycle of arsenic ttrioxide- based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia 显示文摘	Gore SD Gojo I Sekeres MA	2010	J Clin Oncol2010，28，：	1
20	Impact of the putative differentiationg agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia 显示文摘	Gore SD Weng LJ Zhai S	2001	Clin Cancer Res2001，7，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示